| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
We are Körber – an international technology group with more than 12,000 employees at over 100 locations worldwide and a common goal: We turn entrepreneurial thinking into customer success and shape the technological change. In the Business Areas Digital, Pharma, Supply Chain, and Technologies, we offer products, solutions and services that inspire. We act fast to customer needs, we execute ideas seamlessly, and with our innovations we create added value for customers. In doing so, we are increasingly building on ecosystems that solve the challenges of today and tomorrow. Körber AG is the holding company of the Körber Group.
When it comes to the world of automotive components, JVIS has continued to be the supplier of choice for leading global brands. Why? Were fast. Were flexible. Were everywhere. With our extensive art-to-part capabilities, we can do whatever it takes to help our customers get the solution they need. And facilities around the world and an international network of dedicated partners — we can provide global services with localized support you cant get from other suppliers. Thats great news for both your production line and bottom line. Whether you need a sleek new exterior part or a complete interior solution that creates a more comfortable ride, our team of experts can quickly design, produce and deliver exactly what you need.
Pendrick Capital Partners is one of the largest HEALTHCARE debt buyers in the USA providing additional revenue streams to all our clients. Our management team is comprised of industry veterans with over 80 years of combined knowledge. We bring core expertise to all consumer debt segments in our underwriting and servicing processes. We hold ourselves to the highest standards and take pride in our business relationships. Our commitment to customer service is unmatched in the industry, just ask for our references. The sale of aged A/R among HEALTHCARE providers has become much more mainstream over the last 10 years. During the last 3 years, Pendrick Capital Partners has purchased over 55 million accounts with a face value of over $16 billion. These portfolios represent patient accounts at ER physician groups, ambulance companies and hospitals. The desire of providers to implement a profitable, compliant, and sensible solution to their revenue cycle challenges and cash acceleration needs has never been greater. With the right partner, the impact of selling should be no different than the impact of using contingency collection agencies to recover delinquent accounts. In many cases, clients have informed us that this practice has enhanced overall collections, as it creates an expectation of payment within their patient bases. Pendrick Capital Partners recognizes the important role that physicians, clinics and hospitals play in local communities and conducts its business with the highest degree of professionalism and respect for patients and clients. Careful due diligence helps us understand an organization`s unique needs and ensures that our tailored collection efforts meet our clients expectations prior to starting a relationship. We do not resell accounts and strongly recommend that any healthcare provider who is concerned about patient and community relations makes a no-resale provision a non-negotiable part of its business agreement with any debt buyer.
Synonym is accelerating the worlds biological future by developing, financing and building commercial-scale biomanufacturing facilities. We provide synthetic biology (synbio) producers – from startups to the Fortune 500 – with flexible production capacity while giving infrastructure investors access to a new, carbon-negative biomanufacturing asset class that we are calling "fermentation farms".